API | gadoversetamide

gadoversetamide (optimark) Report issue

Small molecule Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW

Gadoversetamide is a gadolinium-based MRI contrast agent, particularly for imaging of the brain, spine and liver. It is marketed under the trade name OptiMARK. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
gadoversetamide

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Organizations (6)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (1)

Diagnostic Imaging (approved 1999)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Brain Diseases (Phase 2)

Pathologic Processes (Phase 4)

Spinal Cord Diseases (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 3
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue